Demographic, immunosuppressive regimen, and virologic data from organ recipients
| Patients . | Sex . | Age, y . | Transplanted organ . | Time from transplantation, mo . | Immunossupressive regimen . | CMV serologic status before transplantation . | CMV viremia, copies/mL . |
|---|---|---|---|---|---|---|---|
| CMV− | |||||||
| 1 | M | 58 | Heart | 156 | CsA/MPA/CS | R+ | ND |
| 2 | M | 45 | Kidney | 168 | Tac/MPA | R+ | ND |
| 3 | M | 63 | Liver | 1 | Tac/MPA/CS | R+ | ND |
| 4 | F | 63 | Kidney | 6 | Tac/MPA/CS | R+ | ND |
| 5 | M | 67 | Kidney | 26 | Tac/MPA/CS | R− | ND |
| CMV+ | |||||||
| 6 | M | 50 | Kidney | 240 | MPA/CS | R+ | 36 000 |
| 7 | M | 56 | Kidney | 8 | Tac/MPA/CS | R− | 480 000 |
| 8 | M | 49 | Kidney | 2 | Jak3i/MPA/CS | R+ | 341 000 |
| 9 | M | 20 | Kidney | 12 | Tac/MPA/CS | R+ | 67 000 |
| Patients . | Sex . | Age, y . | Transplanted organ . | Time from transplantation, mo . | Immunossupressive regimen . | CMV serologic status before transplantation . | CMV viremia, copies/mL . |
|---|---|---|---|---|---|---|---|
| CMV− | |||||||
| 1 | M | 58 | Heart | 156 | CsA/MPA/CS | R+ | ND |
| 2 | M | 45 | Kidney | 168 | Tac/MPA | R+ | ND |
| 3 | M | 63 | Liver | 1 | Tac/MPA/CS | R+ | ND |
| 4 | F | 63 | Kidney | 6 | Tac/MPA/CS | R+ | ND |
| 5 | M | 67 | Kidney | 26 | Tac/MPA/CS | R− | ND |
| CMV+ | |||||||
| 6 | M | 50 | Kidney | 240 | MPA/CS | R+ | 36 000 |
| 7 | M | 56 | Kidney | 8 | Tac/MPA/CS | R− | 480 000 |
| 8 | M | 49 | Kidney | 2 | Jak3i/MPA/CS | R+ | 341 000 |
| 9 | M | 20 | Kidney | 12 | Tac/MPA/CS | R+ | 67 000 |
CsA indicates cyclosporin A; MPA, mycophenolic acid; CS, corticosteroid; R, recipient; ND, not detectable; Tac, tacrolimus; and JAK3i, JAK3 inhibitor.